Robert Harris
Chair
Rob Harris has over 35 years of pharmaceutical industry experience in both Canada and the United States in sales, marketing, business development and general management.
Mr. Harris most recently served as President and CEO of Tribute Pharmaceuticals. Prior to co-founding Tribute Pharmaceuticals, Rob was the President & CEO of Legacy Pharmaceuticals Inc. Mr. Harris also has previous experience at Biovail Corporation where as VP of Business Development he was involved, led and successfully concluded numerous business development transactions, including the licensing of new chemical entities, the acquisition of mature products, the completion of co-promotion deals, distribution agreements, product development and reformulation transactions. Mr. Harris joined Biovail in 1997 as the GM of Biovail Pharmaceuticals Canada at a time when the company experienced rapid growth in the Canadian division.
Before Biovail, Mr. Harris worked in various senior commercial management positions during his twenty-year tenure at Wyeth (Ayerst) including its consumer products and animal health groups and has been involved in numerous product launches during his career. Mr. Harris is also a past member of the Board of Directors of Tribute Pharmaceuticals, Aralez Pharmaceuticals Inc. and CannaRoyalty Corp. d/b/a Origin House.
John C. London, LLB, LLM
Vice Chair
Chair of the Compensation, Corporate Governance & Nominating Committee
Mr. London has over 30 years of experience managing and advising a wide variety of public and private businesses. From 2005 to 2018 Mr. London held senior executive positions with Nuvo Pharmaceuticals and its predecessor Nuvo Research, including Vice Chairman (2005-2009), President and Co-CEO (2009-2016), President and CEO (2016-2017) and Executive Chairman (2018). In January of 2019, he assumed his current role as non-executive Vice Chairman of the Board of Directors.
Mr. London is currently the Chair of the Strategic Advisory Board and Executive in Residence at the John F. Wood Centre for Business and Student Enterprise at the Gordon S. Lang School of Business and Economics at the University of Guelph and is an Advisory Board Member of the Masters of Biomedical Discovery and Commercialization program at McMaster University. Mr. London is also a member for the board of directors of Crescita Therapeutics Inc.
From 2002 to 2005, Mr. London was President and Chief Executive Officer of Powercart Systems Inc., a Canadian-based private company that designs and manufactures battery-equipped workstations that power devices with wireless communication capability. In 1997, Mr. London co-founded Nighthawk Investments, a private venture capital investment firm. In 1994, Mr. London co-founded Triam Automotive Inc., an international automotive parts manufacturer, where he served as Executive Vice-President. Triam completed its initial public offering in 1994 and was sold to Magna International Inc. in 1998. From 1988 to 1993, he was Executive Vice-President, Secretary and General Counsel at Atoma International, Magna’s interior systems group. Prior to joining Magna, Mr. London was a partner with the Toronto law firm of Strathy, Archibald and Seagram (now Gowlings) where from 1981 to 1988 he practiced corporate law with a focus on banking and insolvency.
Mr. London is a graduate of the University of Western Ontario law school and holds a Masters of Law Degree from University College London.
Daniel N. Chicoine, CPA, CA
Director
Mr. Chicoine is currently the Chairman of the Board of Crescita Therapeutics Inc. and Chairman of the Audit Committee and a Director on the Board of NeuPath Health Inc. Previously, Mr. Chicoine served as Nuvo’s Chairman and Co-CEO and was actively involved in its day-to-day operations since 2004. From 2001-2004, Mr. Chicoine served as the Chief Financial Officer at Cosma International, Magna’s body and chassis systems group. Mr. Chicoine served as the President of PowerCart Systems Inc., a Markham-based private company that designs and manufactures battery-equipped workstations that power devices with wireless communication capability.
Previously, he served as Vice Chairman in charge of sales at Triam Automotive Inc. From 1982 to 1993, Mr. Chicoine held various positions at the Magna group of companies, including President and CEO of Atoma International Inc. While Mr. Chicoine was the CEO of Atoma, he succeeded in growing its business from $300 million per annum to $1 billion and effected a major restructuring.
Mr. Chicoine is a graduate of the University of Toronto in commerce and is a Chartered Professional Accountant.
Dale MacCandlish Weil, BSC, MBA, ICD.D
Director
Mrs. Dale Weil was elected to the Board of Directors of Miravo in 2022. She is currently Executive Director of the Teresa Dellar Palliative Care Residence and Montreal Institute for Palliative Care. She is also a Director for Thera Technologies, Tetra Bio-Pharma, the Alliance des maisons de soins palliatifs du Québec and the Association québécoise de soins palliatifs.
Previously, Mrs. Weil was with McKesson Canada Corporation. From 1999 to 2018, she held leadership roles including Vice President and General Manager Pharmaceutical Solutions, Senior Vice President Integrated Healthcare and Pharmaceutical Solutions, Senior Vice President Integrated Healthcare Solutions, Strategy and Business Development, Senior Vice President Retail Banner Management Services, and Senior Advisor to the President. Prior to joining McKesson Canada, Mrs. Weil spent 20 years at John Labatt Ltd., Ault Foods and Parmalat Canada in progressive roles in marketing, research, strategy, sales, and general management. Ms. Weil holds a BSC in Marine Biology, an MBA from McGill University and is a certified director from the ICD Directors Education Program.Anthony E. Dobranowski, BA, MBA, CPA, CA
Lead Director
Chair of the Audit Committee
Private Business Investor. Mr. Dobranowski retired from Magna International Inc., a global automotive parts supplier, in 2007. During his employment with Magna, Mr. Dobranowski was most recently a Vice President of Magna, and prior to that held various executive positions (Vice Chairman, President and CFO) at Tesma International Inc., a publicly traded Magna subsidiary. He was instrumental in the initial public offering of Tesma in 1995, and was involved in all aspects of Tesma’s growth, with particular emphasis on financing, investor relations and M&A activity. Previous to that, Mr. Dobranowski held various senior management positions with other Magna companies. Mr. Dobranowski holds an MBA from the University of Toronto and is also a Chartered Professional Accountant.
Mary Ritchie, BCom, CPA, CA
Director
Ms. Ritchie is the President and Chief Executive Officer of Richford Holdings Ltd., an accounting and investment advisory services firm based in Edmonton, Alberta. Ms. Ritchie has over 30 years of experience in both the public, private and not-for-profit sectors and is a Fellow of CPA Alberta. She is a member of the board of directors and audit committees of Alaris Royalty Corp. (TSX) and EnWave Corporation (TSXV) and is the Chair of the Morien Resources’ Audit Committee. She has been a past director on a number of boards, including the Canada Pension Plan Investment Board, Industrial Alliance Insurance, Financial Services Inc. (TSX), iA Financial Corporation Inc. (TSX) and IPL Plastics Inc. (TSX) and a past member of the RBC Global Asset Management’s independent oversight committee. Ms. Ritchie holds a BCom from the University of Alberta and is a Chartered Professional Accountant.